Nu Skin Enterprises, Inc. logo

Nu Skin Enterprises, Inc.

NUS

NYSEConsumer DefensiveHousehold & Personal Products

Previous close

$4.74

+$0.09 · +1.94%

Aug 21, 4:00 PM ET

Pre-market

$4.74

$0.00 · 0.00%

Aug 24, 4:05 AM ET

NUS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

92

Deep Value

Momentum

23

Weakening

Sentiment

60

Mixed

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageLOC Transformation age-defying lines, innovative devices like the ageLOC LumiSpa for comprehensive skin treatment and cleansing, and the ageLOC Boost, alongside various other cosmetic and personal care items. In the realm of health and nutrition, Nu Skin provides a comprehensive array of dietary and weight management products. This includes ageLOC Youth, LifePak, and ageLOC Meta nutritional supplements, in addition to ageLOC TR90 programs designed for weight control and body contouring, Beauty Focus Collagen+ skin care supplements, and other related weight management aids. The organization also significantly invests in research and development, particularly for its skincare and nutritional supplement portfolios. Nu Skin operates a network of retail stores and customer service centers exclusively within Mainland China. Its extensive product lines are marketed under its proprietary brands, which include Nu Skin, Pharmanex, and ageLOC. These products reach consumers through multiple sales channels, including direct-to-consumer interactions, an extensive network of independent distributors, and its dedicated e-commerce platform. Nu Skin Enterprises, Inc. was established in 1984 and maintains its corporate headquarters in Provo, Utah.

Industry
Household & Personal Products
Sector
Consumer Defensive
Headquarters
US
CEO
Ryan S. Napierski
Listed since
Nov 22, 1996
Employees
2,800

Market position

Day range

Current $4.74

52-week range

Current $4.74

Open
$4.675
Previous close
$4.65
Volume
235.31K
0.36× average
Average volume
659.09K
Average daily volume
Market cap
230.13M USD
Beta
0.97
Market reference 1
50-day average
$5.1126
-7.29% below average
200-day average
$7.6861
-38.33% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
599.82M USD
P/E (TTM)
-1.06×
P/B (TTM)
0.42×
P/S (TTM)
0.17×
EV / EBITDA
2.29×
Earnings yield
33.78%
Free cash flow yield
9.70%
Dividend yield
5.06%

Profitability & efficiency

Gross margin
69.19%
Operating margin
-0.62%
Net margin
-15.73%
Return on equity
19.90%
Return on assets
11.40%
Return on invested capital
6.29%

Financial health

Debt / equity
0.49×
Current ratio
2.08×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%50%16%-17%Gross margin, FY2021: 74.95%Gross margin, FY2022: 71.65%Gross margin, FY2023: 68.93%Gross margin, FY2024: 68.23%Gross margin, FY2025: 69.45%Operating margin, FY2021: 8.68%Operating margin, FY2022: 4.98%Operating margin, FY2023: 2.45%Operating margin, FY2024: -8.75%Operating margin, FY2025: 6.12%Net margin, FY2021: 5.46%Net margin, FY2022: 4.71%Net margin, FY2023: 0.44%Net margin, FY2024: -8.46%Net margin, FY2025: 10.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.95%. Gross margin FY2022 71.65%. Gross margin FY2023 68.93%. Gross margin FY2024 68.23%. Gross margin FY2025 69.45%. Operating margin FY2021 8.68%. Operating margin FY2022 4.98%. Operating margin FY2023 2.45%. Operating margin FY2024 -8.75%. Operating margin FY2025 6.12%. Net margin FY2021 5.46%. Net margin FY2022 4.71%. Net margin FY2023 0.44%. Net margin FY2024 -8.46%. Net margin FY2025 10.79%.

Income trends

Revenue

1.49B USD-14.26%

Operating income

90.88M USD+242.46M USD

Net income

160.2M USD+306.8M USD
Income trends across reported periods2.98B USD1.84B USD702.59M USD−436.31M USDRevenue, FY2021: 2.7B USDRevenue, FY2022: 2.23B USDRevenue, FY2023: 1.97B USDRevenue, FY2024: 1.73B USDRevenue, FY2025: 1.49B USDOperating income, FY2021: 233.99M USDOperating income, FY2022: 110.85M USDOperating income, FY2023: 48.27M USDOperating income, FY2024: −151.59M USDOperating income, FY2025: 90.88M USDNet income, FY2021: 147.27M USDNet income, FY2022: 104.78M USDNet income, FY2023: 8.6M USDNet income, FY2024: −146.59M USDNet income, FY2025: 160.2M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.7B USD. Revenue FY2022 2.23B USD. Revenue FY2023 1.97B USD. Revenue FY2024 1.73B USD. Revenue FY2025 1.49B USD. Operating income FY2021 233.99M USD. Operating income FY2022 110.85M USD. Operating income FY2023 48.27M USD. Operating income FY2024 −151.59M USD. Operating income FY2025 90.88M USD. Net income FY2021 147.27M USD. Net income FY2022 104.78M USD. Net income FY2023 8.6M USD. Net income FY2024 −146.59M USD. Net income FY2025 160.2M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.49B USD1.73B USD1.97B USD2.23B USD2.7B USD
Cost of goods sold453.76M USD550.23M USD611.85M USD630.92M USD675.22M USD
Gross profit1.03B USD1.18B USD1.36B USD1.59B USD2.02B USD
Research and development13M USD22.6M USD27.2M USD
Selling, general, and administrative940.52M USD1.13B USD1.29B USD1.44B USD1.73B USD
Operating expenses940.52M USD1.33B USD1.31B USD1.48B USD1.79B USD
Interest income10.38M USD11.16M USD
Interest expense13.95M USD26.41M USD25.56M USD21.88M USD11M USD
Depreciation and amortization52.26M USD69.81M USD69.22M USD72.51M USD125.02M USD
Operating income90.88M USD−151.59M USD48.27M USD110.85M USD233.99M USD
Net income160.2M USD−146.59M USD8.6M USD104.78M USD147.27M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 3 misses, 1 met estimate
Average EPS surprise
+26.93%
11 comparable reports
Latest EPS result
0.2
Estimate 0.2 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.470.350.240.12Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MetQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 0.38, estimate 0.24, surprise +58.33%, Beat. Q2 2025, reported May 8, 2025: actual 0.23, estimate 0.15, surprise +53.33%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.43, estimate 0.25, surprise +72.00%, Beat. Q4 2025, reported Nov 6, 2025: actual 0.34, estimate 0.3, surprise +13.33%, Beat. Q1 2026, reported Feb 12, 2026: actual 0.29, estimate 0.3, surprise -3.33%, Miss. Q2 2026, reported May 7, 2026: actual 0.14, estimate 0.15, surprise -6.67%, Miss. Q3 2026, reported Aug 10, 2026: actual 0.2, estimate 0.2, surprise 0.00%, Met estimate. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates463.37M409.68M355.98M302.29MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 445.55M USD, estimate 436.05M USD, surprise +2.18%, Beat. Q2 2025, reported May 8, 2025: actual 364.49M USD, estimate 352.06M USD, surprise +3.53%, Beat. Q3 2025, reported Aug 7, 2025: actual 386.14M USD, estimate 376.67M USD, surprise +2.51%, Beat. Q4 2025, reported Nov 6, 2025: actual 364.21M USD, estimate 382.7M USD, surprise -4.83%, Miss. Q1 2026, reported Feb 12, 2026: actual 370.32M USD, estimate 382.7M USD, surprise -3.23%, Miss. Q2 2026, reported May 7, 2026: actual 320.61M USD, estimate 329.7M USD, surprise -2.76%, Miss. Q3 2026, reported Aug 10, 2026: actual 320.11M USD, estimate 345.2M USD, surprise -7.27%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 328.7M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

3 institutions
StifelmaintainHold

NUS peers

ETFs holding NUS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research NUS

research.disclaimer